This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed at $24.39 in the latest trading session, marking a -0.53% move from the prior day.
Bausch Health (BHC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $24.57, marking a +1.78% move from the previous day.
Should Value Investors Pick Bausch Health (BHC) Stock Now?
by Zacks Equity Research
Let's see if Bausch Health Companies Inc. (BHC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q4 results reflect better revenues and a solid contribution from its Government Business and IngenioRx businesses, partly offset by escalating expenses.
Is a Beat in Store for HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have gained from rising admissions and higher revenues.
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bausch Health (BHC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $25.06, marking a +0.56% move from the previous day.
Anthem (ANTM) Gears Up for Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results are likely to reflect gains from increased premiums and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.
UnitedHealth (UNH) Q4 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
UnitedHealth's (UNH) Q4 results reflect higher revenues, driven by segmental contributions, partly offset by steep expenses.
Bausch (BHC) Eye Care Business Files for IPO in the US & Canada
by Zacks Equity Research
Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $27.34, moving -1.51% from the previous trading session.
Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bausch Health (BHC) closed the most recent trading day at $27.79, moving +0.65% from the previous trading session.
Why Is Bausch (BHC) Down 15.6% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.
Bausch Health (BHC) Beats Q3 Earnings Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 6.54% and -1.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Earnings Preview: Bausch Health (BHC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Increase Y/Y
by Zacks Equity Research
Anthem's (ANTM) third-quarter results reflect higher revenues and solid contribution from its segments.
What's in Store for HCA Healthcare's (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q3 results are likely to reflect better revenues owing to higher patient volumes.
Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal
by Zacks Equity Research
Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.
Bausch Health (BHC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AptarGroup (ATR) Buys Stake in Voluntis, Boosts Capabilities
by Zacks Equity Research
AptarGroup (ATR) completes the acquisition of 64.6% stake in Voluntis, which will help expand its digital healthcare offerings and drive innovation in the healthcare space.
Why Is Bausch (BHC) Up 15.2% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.